AU2003901316A0 - Regulation of cell surface proteins - Google Patents
Regulation of cell surface proteinsInfo
- Publication number
- AU2003901316A0 AU2003901316A0 AU2003901316A AU2003901316A AU2003901316A0 AU 2003901316 A0 AU2003901316 A0 AU 2003901316A0 AU 2003901316 A AU2003901316 A AU 2003901316A AU 2003901316 A AU2003901316 A AU 2003901316A AU 2003901316 A0 AU2003901316 A0 AU 2003901316A0
- Authority
- AU
- Australia
- Prior art keywords
- regulation
- cell surface
- surface proteins
- proteins
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000018697 Membrane Proteins Human genes 0.000 title 1
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 230000009134 cell regulation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/382—Cystic fibrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Oncology (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003901316A AU2003901316A0 (en) | 2003-03-21 | 2003-03-21 | Regulation of cell surface proteins |
| EP04722197A EP1622626A1 (en) | 2003-03-21 | 2004-03-22 | Regulation of cell surface proteins |
| PCT/AU2004/000358 WO2004082690A1 (en) | 2003-03-21 | 2004-03-22 | Regulation of cell surface proteins |
| CNA2004800077366A CN1761472A (zh) | 2003-03-21 | 2004-03-22 | 细胞表面蛋白质的调节 |
| CA002517186A CA2517186A1 (en) | 2003-03-21 | 2004-03-22 | Regulation of cell surface proteins |
| AU2004222677A AU2004222677A1 (en) | 2003-03-21 | 2004-03-22 | Regulation of cell surface proteins |
| JP2006503972A JP2006524491A (ja) | 2003-03-21 | 2004-03-22 | 細胞表面タンパク質の調節 |
| US10/549,301 US20060263781A1 (en) | 2003-03-21 | 2004-03-22 | Regulation of cell surface proteins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003901316A AU2003901316A0 (en) | 2003-03-21 | 2003-03-21 | Regulation of cell surface proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003901316A0 true AU2003901316A0 (en) | 2003-04-03 |
Family
ID=31500359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003901316A Abandoned AU2003901316A0 (en) | 2003-03-21 | 2003-03-21 | Regulation of cell surface proteins |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060263781A1 (enExample) |
| EP (1) | EP1622626A1 (enExample) |
| JP (1) | JP2006524491A (enExample) |
| CN (1) | CN1761472A (enExample) |
| AU (1) | AU2003901316A0 (enExample) |
| CA (1) | CA2517186A1 (enExample) |
| WO (1) | WO2004082690A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5140218B2 (ja) | 2001-09-14 | 2013-02-06 | 有限会社コヒーレントテクノロジー | 表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法 |
| US8062500B2 (en) | 2001-12-05 | 2011-11-22 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (ORP) water |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| AU2006226750B2 (en) | 2005-03-23 | 2012-07-19 | Oculus Innovative Sciences, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| MX2007013774A (es) | 2005-05-02 | 2008-01-29 | Oculus Innovative Sciences Inc | Metodo para utilizar solucion de agua con potencial oxido reductor en aplicaciones dentales. |
| WO2007085018A2 (en) | 2006-01-20 | 2007-07-26 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| DK2135081T3 (da) * | 2007-04-16 | 2013-03-11 | Momenta Pharmaceuticals Inc | Fremgangsmåder i forbindelse med celleoverfladeglycosylering |
| CN102480972B (zh) | 2009-06-15 | 2014-12-10 | 奥古露丝创新科学公司 | 含有次氯酸的溶液及其使用方法 |
| CN103228787B (zh) * | 2010-09-28 | 2017-06-23 | 阿贝拉生物科学公司 | 用于分泌性蛋白表达的融合蛋白 |
| AU2019370363B2 (en) * | 2018-10-30 | 2025-07-10 | University Of Florida Research Foundation, Incorporated | Amino acid compositions and methods for treating cystic fibrosis |
| CN111175431A (zh) * | 2020-01-15 | 2020-05-19 | 上海林志生物科技有限公司 | 一种用于肺癌诊断的靶蛋白及其用途、试剂盒 |
| CN115060898B (zh) * | 2021-07-01 | 2025-08-12 | 浙江大学 | 一种检测抗原肌球蛋白1-IgG抗体的试剂盒 |
-
2003
- 2003-03-21 AU AU2003901316A patent/AU2003901316A0/en not_active Abandoned
-
2004
- 2004-03-22 JP JP2006503972A patent/JP2006524491A/ja not_active Withdrawn
- 2004-03-22 WO PCT/AU2004/000358 patent/WO2004082690A1/en not_active Ceased
- 2004-03-22 CN CNA2004800077366A patent/CN1761472A/zh active Pending
- 2004-03-22 EP EP04722197A patent/EP1622626A1/en not_active Withdrawn
- 2004-03-22 CA CA002517186A patent/CA2517186A1/en not_active Abandoned
- 2004-03-22 US US10/549,301 patent/US20060263781A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2517186A1 (en) | 2004-09-30 |
| CN1761472A (zh) | 2006-04-19 |
| JP2006524491A (ja) | 2006-11-02 |
| EP1622626A1 (en) | 2006-02-08 |
| WO2004082690A1 (en) | 2004-09-30 |
| US20060263781A1 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002258941A1 (en) | Methods of enhancing cell responsiveness | |
| AU2003265826A1 (en) | Electrolyte | |
| AU2003290321A1 (en) | Cell cycle progression proteins | |
| AU2003202924A1 (en) | Variation of neural-stimulation parameters | |
| AU2003279766A1 (en) | Microfluidic protein crystallography | |
| AU2003260351A1 (en) | Cell culture insert | |
| AU2003290432A1 (en) | T cell activating gene | |
| AU2003901316A0 (en) | Regulation of cell surface proteins | |
| AU2003252072A1 (en) | Modulation of protein kinase c-iota expression | |
| AU2003902514A0 (en) | Personal support aid | |
| AU2003260787A1 (en) | Protein kinases | |
| AU2003282338A1 (en) | Determination of protein function | |
| AU2003902363A0 (en) | Cell separation | |
| AU2003300492A1 (en) | Sample cell | |
| AU2002950183A0 (en) | Expression of hydrophobic proteins | |
| AU2003215452A1 (en) | Surface proteins of leptospira | |
| AU2003236374A1 (en) | Atopic dermatitis-inducing proteins | |
| AU2003202694A1 (en) | Torero protein | |
| AU2002368450A1 (en) | Radioablation of hemolymphopoietic cell populations | |
| AU2003270055A1 (en) | Neurotransmission-associated proteins | |
| AU2003278718A1 (en) | Stars-a muscle-specification-binding protein | |
| AU2003300785A1 (en) | Carbohydrate-associated proteins | |
| AU2003258699A1 (en) | Minibrain homologous proteins involved in the regulation of energy homeostasis | |
| ZA200501352B (en) | Cell culture surface | |
| HK1085923A (en) | T cell regulation |